Craft
Tollys

Tollys

Total Funding

$6.8 M

Tollys Summary

Company summary

Overview
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company offers TL-532, new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically, and highly specific to the TLR3 receptor.
Type
Private
Founded
2015
HQ
Lyon, FR | view all locations
Website
http://tollys.fr/
Cybersecurity rating
Sectors

LocationsView all

2 locations detected

  • Lyon, Auvergne-Rhône-Alpes HQ

    France

    41 Quai Fulchiron

  • Lyon, Auvergne-Rhône-Alpes

    France

    60 Av. Rockefeller

News

Footer menu